Japan
MOLCURE Inc. has positioned itself as a pioneering force in the biotech sector, integrating cutting-edge technologies to transform drug discovery and design. Founded in 2013 with the compelling slogan, "We are an AI company focusing on accelerating drug discovery & design," the company is headquartered in Japan.
MOLCURE's platform uniquely combines AI, evolutionary molecular engineering, next-generation sequencing, and laboratory automation. With a proprietary database exceeding one billion molecular entries, they deliver highly specific antibodies and peptides. The company's collaborations with innovative partners focus on discovering therapeutics with a broad global impact.
In its latest financial milestone, MOLCURE secured a ¥800.00M Series C investment on 01 August 2021, backed by notable investors such as Japan Post Capital, SBI Investment, Nippon Investment Company, and Strive. The company's dual-focus on AI integration and strategic partnerships positions it as a promising asset in the Biopharma, Biotechnology, and Pharmaceutical sectors.
